We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:

Search Results

Showing 1-20 of 7,161 results
  1. The patients with multiple myeloma were infected with COVID-19 during autologous stem cell transplantation: case report and literature review

    This paper introduces two cases of multiple myeloma, COVID-19 infection during autologous stem cell transplantation, the treatment process, and...

    Chang Su, Lijun Huang, ... Ling **ao in Infectious Agents and Cancer
    Article Open access 27 May 2024
  2. MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation

    Autologous hematopoietic stem cell transplantation (AHSCT) remains the most prevalent type of stem cell transplantation. In our study, we...

    Damian Mikulski, Mateusz Nowicki, ... Wojciech Fendler in Biomarker Research
    Article Open access 23 April 2024
  3. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation

    Autologous stem cell transplantation (autoHCT) is considered standard of care for newly diagnosed multiple myeloma (MM). Although most patients...

    Oren Pasvolsky, Zhongya Wang, ... Muzaffar H. Qazilbash in Blood Cancer Journal
    Article Open access 17 May 2024
  4. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

    Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk...

    Roch Houot, Emmanuel Bachy, ... François Lemonnier in Nature Medicine
    Article Open access 14 September 2023
  5. Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission

    Objective

    To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid...

    Juan Chen, Li Liu, ... Sizhou Feng in Cancer Cell International
    Article Open access 31 October 2022
  6. MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation

    Background

    Relapse is a frequent occurrence in autologous hematopoietic stem cell transplantation (AHSCT), and early relapse after AHSCT results in...

    Mohammad Rafiee, Fatemeh Amiri, ... Abbas Hajifathali in BMC Cancer
    Article Open access 03 March 2023
  7. Treatment benefit of upfront autologous stem cell transplantation for newly diagnosed multiple myeloma: a systematic review and meta-analysis

    Background

    Upfront high-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains a profitable strategy for newly diagnosed...

    Chi-Maw Lin, Lih-Chyun Chang, ... Feng-Ming Tien in BMC Cancer
    Article Open access 16 May 2023
  8. Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation

    Background

    Several studies showed that lack of CD56 expression was a poor prognostic factor for patients with newly diagnosed multiple myeloma (NDMM)....

    Chuanying Geng, Huixing Zhou, ... Wenming Chen in BMC Cancer
    Article Open access 23 December 2022
  9. Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation

    This study aimed to identify the benefits of autologous-stem cell transplantation (auto-SCT) and allogeneic-SCT (allo-SCT) in patients with...

    Dong Won Baek, Joon Ho Moon, ... Sang Kyun Sohn in Blood Cancer Journal
    Article Open access 26 June 2023
  10. Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years

    Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large...

    Philipp Berning, Mathilde Fekom, ... Norbert Schmitz in Blood Cancer Journal
    Article Open access 05 July 2024
  11. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma

    Background

    Autologous stem-cell transplantation (ASCT) remains a beneficial approach for patients with newly diagnosed multiple myeloma (NDMM) in the...

    Yi Tao, Shiwei **, ... Jianqing Mi in BMC Cancer
    Article Open access 02 April 2024
  12. Intracerebral Transplantation of Autologous Mesenchymal Stem Cells Improves Functional Recovery in a Rat Model of Chronic Ischemic Stroke

    While treatments exist for the acute phase of stroke, there are limited options for patients with chronic infarcts and long-term disability....

    Max I. Myers, Kevin J. Hines, ... Lorraine Iacovitti in Translational Stroke Research
    Article Open access 02 November 2023
  13. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update

    The current standard of care model for newly diagnosed fit multiple myeloma (NDMM) patients is the sequential treatment of induction, high dose...

    Abdul Hamid Bazarbachi, Rama Al Hamed, ... Mohamad Mohty in Blood Cancer Journal
    Article Open access 28 March 2022
  14. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database

    Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the...

    Julie Côté, Richard LeBlanc, ... Donna Reece in Blood Cancer Journal
    Article Open access 05 September 2023
  15. Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation

    Background

    To date, there is no information on the safety and efficacy of the novel anti-sarbecoviruses monoclonal antibody sotrovimab administered,...

    Gianpaolo Marcacci, Nicola Coppola, ... Antonio Pinto in Infectious Agents and Cancer
    Article Open access 03 August 2022
  16. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

    Autologous hematopoietic stem cell transplantation (ASCT) improves survival in multiple myeloma (MM). However, many individuals are unable to collect...

    Zachary D. Crees, Michael P. Rettig, ... John F. DiPersio in Nature Medicine
    Article Open access 17 April 2023
  17. Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis

    Experimental allergic encephalomyelitis (EAE) is the animal model of multiple sclerosis (MS). Autologous hematopoietic stem cell transplantation...

    Kaja Kasarełło, Emilian Snarski, ... Agnieszka Cudnoch-Jędrzejewska in Archivum Immunologiae et Therapiae Experimentalis
    Article Open access 28 June 2021
  18. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant

    Background

    There is paucity of data regarding outcomes of children, adolescents and young adults (CAYA) patients with non-Hodgkin lymphoma (NHL)...

    Oren Pasvolsky, Roland L. Bassett, ... Yago Nieto in BMC Cancer
    Article Open access 20 December 2023
Did you find what you were looking for? Share feedback.